In rare diseases less biotech companies doing rese
Post# of 148187
(Total Views: 228)
Posted On: 07/11/2019 10:38:37 AM
In rare diseases less biotech companies doing research , there are not many patients to go after , this is probably why phase 1 to approval is little higher...
In unmet need actually more biotech doing research....especially if it is not a rare problem , like breast cancer...
Those are usual differences between those two ....
In unmet need actually more biotech doing research....especially if it is not a rare problem , like breast cancer...
Those are usual differences between those two ....
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼